<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3110246132
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FOSTER PRESSURISED SOLUTION FOR INHALATION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BECLOMETHASONE DIPROPIONATE,FORMOTEROL FUMARATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100,6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Pressurised inhalation, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pressurised container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        17
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        102.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CHIESI FARMACEUTICIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CHIESI FARMACEUTICIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CHIESI FARMACEUTICIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Foster is a pressurised inhalation solution containing two active substances which are in-haled through your mouth and delivered directly into your lungs.The two active substances are beclometasone dipropionate and formoterol fumarate dihy-drate. Beclometasone dipropionate belongs to a group of medicines called corticosteroids which are often referred to simply as steroids and have an anti-inflammatory action reducing the swelling and irritation in the walls of the small air passages in the lungs. Steroids are used in asthma to help to treat symptoms and prevent symptoms.Formoterol fumarate dihydrate belongs to a group of medicines called long-acting bronchodi-lators which relax the muscles in your airways and by doing this widen the airways which makes it easier for you to breathe air in and out of your lungs.Together these two active substances make breathing easier, by providing relief from symp-toms such as shortness of breath, wheezing and cough in patients with asthma and also help to prevent the symptoms of asthma.Foster is intended in the regular treatment of people with asthma in whom:asthma is not adequately controlled by using inhaled corticosteroids and &ldquo;as needed&rdquo; short-acting bronchodilatorsorasthma is responding well to treatment with both corticosteroids and long-acting bronchodilators</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. therefore, when treating patients with asthma, theproduct should only be used for patients not adequately controlled on other asthma-controller medications (e.g. low-to medium dose inhaledcorticosteroids) or whose disease severity clearly warrants ini-tiation of treatment with two maintenance therapies.Do not use Foster:Do NOT use this medicine to treat acute symptoms of asthma such as shortness of breath, wheezing and coughor for asthma which is getting worse or for acute asthma attacks. It will not help you and it will not provide immediate relief of your symptoms. To relieve your symptoms you should use your quick-acting &ldquo;reliever&rdquo; inhaler which you should carry with you at all times. (Your &ldquo;reliever&rdquo;inhaler is a quick-acting bronchodilator which should provide rapid relief of acute asthma symptoms).if you are allergic or think you are allergic to one or other of the active ingredients of Fos-ter or if you are allergic to other medicines or inhalers used to treat asthmaor to any of the other ingredientsof Foster(see section 6: Further Information), contact your doctor for advice.</p><p>Take special care with Fosterand always tell your doctorbefore using Foster:If you have any heart problems, such as angina (heart pain, pain in the chest), a recent heart attack (myocardial infarction), heart failure, narrowing of the arteries around your heart (coronary heart disease) valvular heart disease or any other known abnormalities of your heart or if you have a condition known as hypertrophic obstructive cardiomyo-pathy (also known as HOCM, a condition where the heart muscle is abnormal). If you have narrowing of the arteries (also known as arteriosclerosis), if you have high blood pressure or if you know that you have an aneurysm (an abnormal bulging of the blood vessel wall).If you have disorders of your heart rhythm such as increased or irregular heart rate, a fast pulse rate or palpitations or if you have been told that your heart trace is abnormal.If you have an overactive thyroid gland.If you have low blood levels of potassiumIf you have any disease of your liver or kidneys.If you have diabetes (if you inhale high doses of formoterol your blood glucose may increase and therefore you may need to have some additional blood tests tocheck your blood sugar when you start using this inhaler and from time to time during treat-ment).If you have a tumour of the adrenal gland (known as a phaeochromocytoma) &ndash;If you are due to have an anaesthetic. Depending on the type of anaesthetic, it may be necessary to stop taking Foster at least 12 hours before the anaesthesia.If you are being, or have ever been, treated for tuberculosis (TB) or if you have a known viral or fungal infection of your chest. If you must avoid alcohol because you suffer from any of the following diseases or conditions: liver disease, alcoholism, epilepsy, any brain injury or disease</p><p>&nbsp;</p><p>If any of the above apply to you, always inform your doctor before you use Foster. If you have or had any medical problems or any allergies or if you are not sure as to whether you can use Foster talk to your doctor, asthma nurse or pharmacist before using the inhaler.Treatment with a beta-2-agonist like the formoterol contained in Foster can cause asharpfall in your serum potassiumlevel (hypokalaemia). If you have severe asthma, you should take special care.This is because a lack of oxy-gen in the bloodand some other treatments you may be taking together with Foster, such as medicines for treating heart disease or high blood pressure, known as diuretics or &ldquo;water tablets&rdquo; or other medicines used to treat asthma can make the fall in potassium level worse.For this reason your doctor may wish to measure the potassium levels in your blood from time to time. If you take higher dosesof inhaled corticosteroids over longperiods,you may have more of a need for corticosteroids in situationsof stress. Stressful situations mightincludebeingtakento hospital after an accident, having a serious injury or before an operation. In this case, the doctor treating you will decide whether you may need to increase your dose of corticosteroids and may prescribe some steroid tablets or a steroid injection.Should you need to go to the hospital, remember to take all of your medicines and inhalerswith you including Foster and any medicines or tablets bought without a prescription, in their original package, if possible.Using Foster with other medicines:Before starting treatment, please tell your doctor or pharmacist if you are taking or have re-cently taken any other medicines, including any other inhalers and including medicines ob-tained without a prescription.Do not use beta blockerswith this medicine. If you need to use beta blockers (including eye-drops), the effect of formoterol may be reduced or formoterol may not work at all. On the otherhand, usingother beta adrenergic drugs (drugs which work in the same way as for-moterol) may increase the effectsof formoterol</p><p>Using Foster togetherwith: medicinesfor treating abnormal heart rhythms (quinidine, disopyramide, procaina-mide), medicines used to treat allergic reactions(antihistamines), medicines for treat-ing symptoms of depressionor severe mental disorders such as monoaminoxidase inhibitorsMAOI&rsquo;s(for example phenelzine and isocarboxazid), tricyclic antidepres-sants(for example amitryptiline and imipramine), phenothiazinescan cause somechanges in the electrocardiogram(ECG, heart trace). They may also increase the risk of disturbances of heart rhythm (ventricular arrhythmias).medicines for treating Parkinson&rsquo;s Disease(L-dopa), to treat an underactive thyroid gland (L-thyroxine), medicines containing oxytocin (which causes uterine contraction) and alcohol can lower your heart&rsquo;stolerance to beta-2-agonists, such as formoterol.monoaminoxidase inhibitors(MAOIs), including drugs with similar propertieslike fura-zolidone and procarbazine,used to treat mental disorders, can cause a rise in blood pressure.medicines for treating heart disease(digoxin) can cause a fall in your bloodpotassi-um level. This may increase the likelihood of abnormal heart rhythms.</p><p>other medicines used to treat asthma (theophylline, aminophylline or steroids)and diuretics (water tablets) may cause a fall in your potassium level. Some anaesthetics can increasethe risk of abnormalheart rhythms.Pregnancy and breast feedingThere are no clinical data on the use of Foster during pregnancy. Foster should not be used if you are pregnant, think that you might be pregnant or are plan-ning to become pregnant, or if you are breast-feeding, unless you are advised to do so by your doctorDriving and using machinesFoster is unlikely to affect your ability to drive and use machines.Important information about some of the ingredients of FosterFoster containsa small amount of alcohol. Every aerosol puff from your inhaler contains 7 mg of ethanol.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Foster is for inhalation use.Always use Foster exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.Your doctor will give you a regular check-up to make sure you are taking the optimaldose of Foster. Your doctor will adjust your treatment to the lowest dose that best controls your symptoms. Under no circumstancesshould you change the dose without first speaking to your doctor.Adults and the elderly:The usual dose of this medicine is one or two puffs twice daily.The maximum daily dose is 4 puffs.Childrenless than 12 years of age and adolescents aged 12-18 years:Children less than 12 years of age and adolescents aged between 12-18must NOTtake this medicine.At-risk patients:Older people do not need to have their dose adjusted. No information is available regarding the use of Foster in people with liver or kidney problems.Foster is effective for the treatment of asthma in a dose of beclometasone dipropio-nate which may be lower than that of some other inhalers containing beclometasone dipropionate. If you have been using a different inhaler containing beclometasone dipropionate previously, your doctor will advise you on the exact dose of Foster you should take for your asthma.Remember: you should always have your quick-acting &ldquo;reliever&rdquo; inhaler with you at all timesto treat worsening symptoms of asthma or a sudden asthma attack. Instructions for use:Beforeusing the inhaler for the first time or if you have not used the inhaler for 14 days or more, releaseone puff into the air to make sure the inhaler is workingproperly. Wheneverpossible, stand or sit in an upright position when inhaling.</p><p>1. Remove the protective cap from the mouthpieceand check that the mouthpiece is clean and free from dust and dirt or any other foreign objects.2. Breath out as slowly and deeply as possible3. Hold the canister vertically with its body upwards and put your lips around the mouth-piece. Do not bite the mouthpiece,4. Breathe in slowly and deeply through your mouth and, just after starting to breathe in, press down on the top of the inhaler to release one puff 5. Hold your breath for as long as possible and,finally, remove the inhaler from your mouth and breathe outslowly. Do not breath into the inhaler.After use, close with the protective cap.</p><p>If you see &#39;mist&#39; coming from the top of the inhaler or the sides of your mouth you should start again from step 2.If you have weak hands,it may be easier to hold the inhaler with both hands: hold the upper part of the inhaler with both index fingers and its lower part with both thumbs.To lowerthe risk of a fungal infection in the mouth and throat, rinse your mouth or gargle with water or brush your teeth each time you use your inhaler.If you think the effect of Foster is too muchor not enough, tell your doctor or pharmacist.No data are available regarding the use of Foster with a spacing device. The dosestated in this leafletrefers to the inhalation of Foster using a standard inhaler. Do NOT useFoster with any spacing device. If you need to use a spacing device, your doc-tor may advise you to stop using Foster and may prescribe you another medicine to treat your asthma.CleaningRemove the cap from the mouthpiece and regularly (once weekly) wipe the outside and in-side of the mouthpiece with a dry cloth. Do not use water or other liquids to clean the mouth-piece.Do not increase the doseIf you feelthat the medicine is not very effective, always talk to your doctor beforeincreasing the dose. If you use more Foster than you should:</p><p>&nbsp;</p><p>Taking more formoterol than you shouldcan have the following effects: feeling sick, be-ing sick, heart racing, palpitations, disturbances of heart rhythm, certain changes in the electrocardiogram (heart trace), headache, trembling, feeling sleepy, too much acidin the blood, low blood potassium levels, high levels of glucose in the blood. Your doctor may wish to carry out some blood tests to check your blood potassium and blood glucose lev-els. Taking too muchbeclomethasone dipropionate can lead short-term problems with your adrenal glands. This will get betterwithin a few days however, your doctor may need to check your serum cortisol levels.Tell your doctor if you haveany of these symptoms.If you forget to use Foster:Take it as soon as you remember. If it is almost time for your next dose, do not take the dose you have missed, just take the next dose at the correct time. Do not double the dose.If you stop using Foster:Do not lowerthe dose or stop using the medicationyourself.Even if you are feeling better, do not stop taking Foster or lower the dose. If you want to do this, talk toyour doctor. It is very important for you to use Foster regularly even though you may have no symptoms.If your breathing gets worse:If you developworsening shortness of breathwhich has become worse or wheezing(breathing with an audible whistling sound), straight after inhaling your medicine, stop using Foster inhalerimmediately and use your quick-acting &ldquo;reliever&rdquo; inhaler straight-away. You should contact your doctor straightaway. Your doctor will assess your symptoms and if necessary may start you on a different course of treatment. You may be told that youshould not use Foster again. You should always carry your &ldquo;reliever&rdquo; inhalerwith you at all times.Shortness of breath and wheezing which occurs immediately after using your inhaleris caused by acute narrowing of the airways in your lungs and is known as paradoxical bron-chospasm. See also section 4.Possible side effects.If your asthmagets worse:If your symptoms get worse or are difficult to control (e.g. if you are using your &quot;releiver&quot; in-haler more frequently),or if your &quot;releiver&quot; inhaler does not improve your symptoms, see your doctor immediately. Your asthma may be getting worseand your doctor may need to change your dose of Foster or prescribe alternative treatment.If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Foster can cause side effects, although not everybody gets them.Howev-er, many users of this inhaler may not have any problems at all.Possible side effects are listed below according to their frequency. Common(affecting less than 1 in 10people):Headache, hoarseness, sore throat.Uncommon(affecting less than 1 in 100 people);Palpitations, unusual fast heart beat and disorders of heart rhythm, some changes in the electrocardiogram (ECG),</p><p>Flu symptoms, fungal infections (of the mouthand throat), fungal infections of the vagina, inflammation of the sinuses, rhinitis, inflammation of the ear, throat irritation, cough and pro-ductive cough, asthma attack.Nausea, abnormal or impaired sense of taste, burning of the lips, dry mouth, swallowing diffi-culties, indigestion, upsetstomach, diarrhoea.Pain in muscle and muscle cramps, reddening of the face, increased blood flow to some tis-sues in the body, excessive sweating, trembling, restlessness, dizziness.Alterations of some constituents of the blood: a fall in the number of white blood cells, in-creasein the number of blood platelets, a fall in the level of potassium in the blood, increase in blood sugar level, increase in the blood level of insulin, free fatty acid and ketones.Rare (affecting less than 1 in 1,000 people)Feeling chest tightness, missed heartbeat (caused by too early contraction of the ventricles of the heart), increased or decrease in blood pressure, inflammation of the kidney, swelling of skin and mucous membrane persisting for several days, nettle rash or hives. Very rare(affecting less than 1 in 10,000 people)Irregular heart beat, shortness of breath, worsening of asthma, abnormal behaviour, sleep disorders and hallucinations, a fall in the number of blood platelets, swelling of the hands and feet.Using high-dose inhaled corticosteroids over a long time can cause in very rare cases systemiceffects: these includeproblems with how your adrenal glands work (adrenosup-pression), decrease in bone mineral density (thinning of the bones), growth retardation in children and adolescents, increased pressure in your eyes (glaucoma), cataracts. Hypersensitivityreactions like skin allergies, skin itching, skin rash, reddening of the skin, swelling of the skin or mucous membranes especially of the eyes, face, lips and throatmay occur.As with other inhaler treatments there is a risk of worsening shortness of breath and wheez-ing immediately after using Foster and this is known as paradoxical bronchospasm. If this occurs you should STOP using Foster immediatelyand use your quick-acting &ldquo;reliever&rdquo; inhaler straightaway to treat the symptoms of shortness of breath and wheezing. You should contact your doctor straightaway. Your doctor is likely to assess your asthma and if neces-sary may start you on another course of treatment. You may be told that you should not use Foster again.If you experience any of above side effects and they cause you distress, are severe or lastfor several days, or if you feel unwell or notice anything unusual or a side effect which is not mentioned in this leaflet, or if you are worried in any way or if there is anything you do not understand, you should contact your doctor or pharmacistimmediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach andsight of children.Do not use Foster beyond 2 months from the date you get the inhaler from your pharmacist and never use after the expiry date which is stated on the carton and label. Do not store the inhalerabove 30 &deg;C.If the inhaler has been exposed to severe cold, take the canister out of the mouthpiece and warm it with your hands for a few minutes before using. Never warm it by artificial means.</p><p>Warning: The canister contains a pressurised liquid. Do not expose the canister to tempera-tures higher than 50 &deg;C. Do not pierce the canister.Medicines should not be disposed via waste water or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the en-vironment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Foster contains:The active substances are: beclometasone dipropionate, formoterol fumarate dihydrate.Each actuation/metered dose from the inhaler contains100 microgramsof beclometasone dipropionate and 6 micrograms of formoterol fumarate dihydrate. This corresponds to a de-livered dose from the mouthpiece of 84.6 micrograms of beclometasone dipropionate and 5.0 micrograms of formoterol fumarate.The other ingredients are: ethanolanhydrous, hydrochloric acid, propellant: norflurane(HFA 134-a).What Foster looks like and contents of the pack:Foster is a pressurised solution contained in analuminium canister with a metering valve, fitted in a polypropylene plastic actuator with a plastic protective cap. Each pack contains one canister which provides 120 actuations (puffs).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Foster contains:The active substances are: beclometasone dipropionate, formoterol fumarate dihydrate.Each actuation/metered dose from the inhaler contains100 microgramsof beclometasone dipropionate and 6 micrograms of formoterol fumarate dihydrate. This corresponds to a de-livered dose from the mouthpiece of 84.6 micrograms of beclometasone dipropionate and 5.0 micrograms of formoterol fumarate.The other ingredients are: ethanolanhydrous, hydrochloric acid, propellant: norflurane(HFA 134-a).What Foster looks like and contents of the pack:Foster is a pressurised solution contained in analuminium canister with a metering valve, fitted in a polypropylene plastic actuator with a plastic protective cap. Each pack contains one canister which provides 120 actuations (puffs).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The National Pharmacovigilance and Drug Safety Center (NPC)Fax +966-11-205-7662Call NPC at +966-11-2038222, Exts 2317-2356-2353-2354-2334-2340Tool Free Phone: 8002490000E-mail: npc.drug@sfda.gov.saWebsite: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                na
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يعتبر فوستر محلولاً مضغوطاً للإستنشاق ، يحتوي على مكونين فعالين يتم إستنشاقهما عبر فمك ليتم توصيله مباشرةً إلى داخل رئتيك.<br />المكونين الفعالين في المحلول هما :بيكلوميثازون دايبروبيونيت ، وفورموتيرول فوماريت دايهدريت .ينتمي مكون بيكلوميثا زون دايبروبيونيت لمجموعة من العقاقير يطلق عليها إسم&nbsp;كورتيكوسترويدز&nbsp;&quot;Corticosteroids&quot;<br />التي لها مفعول مضاد للإلتهاب يقلل من الأورام والتهيج في الرئتين.</p><p>أما مكون فورموتيرول فوماريت ديهادريت&nbsp;Formoterol Fumarate Dihydrate ، فإنه&nbsp;<br />ينتمي إلى مجموعة من الأدوية إسم برونكوديالايترز&nbsp;&quot;Bronchodilators&quot;، موسعات الشعب الهوائية الطويلة المفعول ، التي تعمل على تهدئة واسترخاء العضلات في رئتيك.</p><p>يعمل هذان المكونان النشطان معاً، على تسهيل عملية التنفس ضمن طريق التخفيف من أعراض مثل ضيق التنفس ، الأزيز التنفسي والسعال ، لدى المرضى المصابين بالربو، أو مرض الإنسداد الرئوي المزمن ويساعدان كذلك في الوقاية من أعراض الربو.</p><p>الربو:</p><p>يشار إلى دواء فوستر لعلاج الربو المنتظم عند الأشخاص البالغين ، الذين يكون:</p><ul><li>الربو لديهم لم تتم السيطرة عليه بصورة كافية بإستخدام مجموعة عقاقير كورتيكوستيرويدز المستنشقة ، وكما هو مطلوب موسعات الشعب الهوائية قصيرة المفعول&quot;Bronchodilators&quot;.</li></ul><p>أو&nbsp;</p><ul><li>الربو لديهم يستجيب جيداً للعلاج مع كل من مجموعة كورتيكوستيرويدز وموسعات الشعب الهوائية &quot;Bronchodilatores&quot;.</li></ul><p>الإنسداد الرئوي المزمن:</p><ul><li>يمكن إستخدام دواء فوستر أيضاً في علاج أعراض الإنسداد الرئوي المزمن الحاد عند الأشخاص البالغين.</li><li>يعتبر الإنسداد الرئوي المزمن مرض طويل المدى للشعب الهوائية في الرئة والتي تحدث بالدرجة الأولى نتيجة تدخين السجائر.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مثبطات بيتا 2 الطويلة المفعول قد تزيد من خطر الموت المرتبط بالربو ولذلك عند معالجة المرضى الذين يعانون من الربو فأن هذا المنتج يستخدم فقط للمرضى اللذين لايتم السيطرة على مرضهم بإستخدام أدوية الربو الأخرى مثال عقار الكورتيكوسيرويد بواسطة الإستنشاق في الحالات الخفيفة إلى المتوسطة أو في الحالات الشديدة والتي تتطلب إستخدام مكونين علاجيين في آن واحد</p><p>&nbsp;</p><p>لا تستعمل فوستر :إن كنت تعاني من التحسس ، أو تعتقد بأنك مصاب بالحساسية من أحد المكونات الفعالة لدواء فوستر ، أو أي منها أو إذا ما كنت مصاباً بالحساسية من أدوية أخرى ، أو أجهزة الإستنشاق المستخدمة لعلاج الربو ، أو لأي من المكونات الأخرى لدواء فوستر ،( أنظر إلى قسم ٦: مزيداً من المعلومات )، إتصل بطبيبك للنصح والإستشارة.</p><p>التحذيرات والإحتياطات:<br />أخبر طبيبكً أو الصيدلي أو الممرضة قبل إستعمالك لدواء فوستر:</p><ul><li>إذا كنت تعاني من أي مشاكل في القلب ، مثل الذبحة (ألم في القلب) ، أو ألم في الصدر ، إذا ما كنت قد أصبت منذ عهد قريب بنوبة قلبية ،( إحتشاء عضلي قلبي )، قصور القلب ، ضيق شرايينك التاجية (مرض القلب التاجي)، مشاكل في صمامات القلب ، أو أي حالات أخرى غير سوية معروفة بالقلب ، أو إذا ما كنت تعاني من حالة يطلق عليها إعتلال قلبي إنسدادي يؤدي &ldquo;Hypertrophic obstructive cardiomyopathy&rdquo; وهي إحدى الحالات التي تكون (HOCM إلى ضخامة عضلة القلب ، (يعرف أيضاً بصفة فيها عضلة القلب غير سوية.</li><li>إذا كنت مصاباً بضيق الشرايين ( المعروف أيضاً بإعتباره تصلب الشرايين) أو إذا كنت تعاني من إرتفاع ضغط الدم ، أو إذا ما كنت تعرف بأنك من مرضى &quot;ِAneurysm&quot; (وهو&nbsp;الإنتفاخ غير السوي لجدران الأوعية الدموية).</li><li>إذا كنت تعاني من إضطراب حركة القلب ، مثل زيادة ، أوعدم إنتظام معدل ضربات القلب نبضاً سريعا أو خفقانا ، أو إذا ما كان قد تم إخبارك بأن عملية تتبع قلبك غير سوية.</li><li>إذا كنت تعانى من نشاط مفرط للغدة الدرقية .</li><li>إذا كنت تعاني من انخفاض مستويات البوتاسيوم بالدم .</li><li>إذا كنت مصاباً بأي مرض كلوي ، أو كبدي.</li><li>إذا كنت مصاباً بداء السكري ( واستنشقت جرعات عالية من مادة فورموتيرول ، فإن جلوكوز دمك قد يزيد ، وقد تكون لذلك محتاجاً فحوصات إضافية للدم لمراقبة مستوى سكر الدم لديك ، عند بدئك إستخدام جهاز الإستنشاق هذا ، وكذلك من وقتٍ لآخر أثناء العلاج)</li><li>إذا ما كنت مصاباً بورم الغدة الكظرية يسمى&nbsp;(Phaeochromocytoma)</li><li>إذا كنت على وشك أن تخضع للتخدير ، إعتماداً على نوع المخدر ، فقد يكون من&nbsp;الضروري أن تتوقف عن تناول دواء فوستر ، قبل 12 ساعة على الأقل من موعد الخضوع للبنج.</li><li>إذا كنت تحت العلاج ، أو تعالجت من داء السل&nbsp;(TB) ، أو إذا كنت مصاباً بمرض رئوي&nbsp;فيروسي ، أو فطري .</li><li>إذا ما كان يتوجب عليك تفادي تناول الكحول لأي سبب .</li><li>إذا كانت أي من الحالات أعلاه تنطبق عليك ، يجب عليك دائماً القيام بإخطار طبيبك عنها قبل إستخدامك لدواء فوستر.</li></ul><p>إذا ما كنت مصاباً حالياً ، ، أو سبق لك أن أصبت بأي مشاكل طبية ، أو أي حالات تحسسية ، أوإذا ما كنت غير متأكد ما إذا كان بمقدورك إستعمال دواء فوستر ، تحدث إلى طبيبك ، أو ممرضة الربو ، أو الصيدلاني ، قبل قيامك بإستعمال جهازالإستنشاق.</p><p>إن التداوي بمادة محفزات بيتا ٢ (BETA - 2- AGONSIT) كتلك المضمنة في دواء فوستر، قد تسبب&nbsp;نفصاً حاداً خطيراً في مستويات مادة البوتاسيوم في دمك (hypokalemai)</p><p>إذا كنت مصاباً بربو حاد ، عليك أن تكون حذراً بصور ة خاصة .ذلك لأن أي نقص في الأكسجين في الدم وبعض من العلاجات التي تتناولها مع دواء فوستر مثل أدوية لعلاج مشكلات القلب ، أو إرتفاع ضغط الدم ، المعروفة بمدرات البول ، أو أقراص الماء ( Water Tablets )<br />أو أدوية أخرى تستعمل في علاج الربو قد تجعل من مستويات النقص والإنخفاض في معدلات البوتاسيوم أسوأ وأكثر تفاقماً .لهذا السبب ، فإن طبيبك قد يري في مراقبة معدلات البوتاسيوم في دمك بصورةٍ منتظمة من وقت لأخر.</p><p>إذا كنت قد تناولت جرعات عالية من مادة كورتيكوستيرويدز ، لفترات طويلة ، فإنك قد تحتاج إلى جرعات أعلى من مجموعة مكونات كورتيكوستيرويدز في حالات الضغط .وحالات الضيق والشد قد&nbsp;تشمل ، أخذك للمستشفى بعد حادثٍ ما أو تعرضك لإصابة خطيرة ، أو ضرورة خضوعك لعملية جراحية .أن طبيبك في هذه الحالات ، بمقدوره أن يقرر ما إذا كان عليه زيادة جرعتك من&nbsp;مكون كورتيكوستيرويدز ، أم لا وأن يصف لك أقراص استيرويد ، أو حقنة استيرويد.<br />تذكر إذا ما كان يجب عليك الذهاب إلى المستشفى أن تأخذ معك كافة أدويتك وأجهزة إستنشاقك ، بما فيها دواء فوستر وأي أدوية ، أو أقراص إشتريتها بدون وصفة طبية وهي في أغلفتها وعبواتها الأصلية ، إن أمكن.<br />إتصل بطبيبك اذا كنت تعاني من رؤية غير واضحة أو أي اضطرابات بصرية أخرى .</p><p>الأطفال والمراهقين:<br />يجب ألا يتناول الأطفال والمراهقين هذا الدواء حتى تتوفر معلومات عن ذلك.</p><p>&nbsp;</p><p>إستخدم فوستر مع أدوية أخرى:<br />رجاءاً. قبل بدئك في العلاج . إخبار طبيبك ، أو الصيدلاني ، إذا ما كنت تتناول ، أو تناولت قريباً أي أدوية أخرى ، بما في ذلك ، أي أدوية حصلت عليها بدون وصفة طبية رسمية.<br />بعض الأدوية قد تزيد من تأثير دواء فوستر وربما قد يرغب طبيبك بمراقبتك بعناية في حالة إستخدام هذه الأدوية (التي تشمل بعض الأدوية لعلاج فيروس نقص المناعة مثل ريتوناڤير،كوبيسيستات)<br />لاتستخدم مضادات بيتا مع هذا الدواء ..إذا ما إستعملت مضادات بيتا (بما في ذلك قطرات العين) ، فإن أثر دواء فورموتيرول قد يضمحل ويخفت ، أو قد لا يعمل إطلاقاً .ومن الناحية الأخرى ، إن&nbsp;إستعمال عقاقير بيتا الأدرنالين &quot;Beta Adrenergic&quot; (العفافير التي تعمل بنفس الطريقة التي&nbsp;يعمل بها عقار فورموتيرول )، قد تزيد من مفعول دواء فورموتيرول.</p><p>إستعمال فوستر مع:</p><ul><li>الأدوية التي تستعمل لعلاج عدم إنتظام وتناسق حركة القلب غير السوية (كوينيداين ،&nbsp;دايسوبايرامايد، بروكاينامايد) ، الأدوية المستعملة لعلاج التفاعلات التحسسية (مضادات الهستامين)، الأدوية المستعملة لعلاج اعراض الإكتئاب ، أو الإضرابات العقلية ، مثل مثبطات مونواماين أوكسيديز (MAOIs) (مثلاً&nbsp;فينيلزاين وايسوكاربوكسازايد) ،&nbsp;ترايسيكليك المضادة للإكتئاب (مثل: اميتريبتيلين واميبراماين و فينوثايزن) قد تسبب بعض&nbsp;التغيرات في مخطط كهربائية القلب (ECG)&nbsp;لمتابعة حالة وحركة القلب . وقد تسبب كذلك&nbsp;زيادة من خطورة اضطرابات عمل القلب وحركته (عدم انتظام البطين) (ventricular arrhythmias)</li><li>الأدوية المستخدمة لعلاج مرض الباركونسون (L-dopa)، الأدوية المستخدمة لعلاج الغدة الدرقية الكسولة (L-Thyroxine) ،&nbsp;الأدوية التي تحتوي على أوكسيتوسين (الذي&nbsp;يسبب تقلصات الرحم )&nbsp;والكحول الذي بمقدورة التقليل من تحمل قلبك لمادة مضادات بيتا. ٢ (Beta-2 Agonists)&nbsp;مثل دواء فورموتيرول .</li><li>إن مثبطات مونوامين أوكسيدز (Monoamine oxidase)، (MAOIs) -&nbsp;بما في ذلك&nbsp;تلك الأدوية التي لها خصائص مماثلة ،مثل فيورازوليدون وبروكاربازين المستعملة في&nbsp;علاج الإضطرابات الفعلية.قد تسبب إرتفاع ضغط الدم .</li><li>قد تسبب الأدويه المستخدمة لعلاج إضطرابات القلب (digoxin)، هبوط في مستوى&nbsp;بوتاسيوم الدم . وهذا قد يزيد من إحتمال نشوء حركة غير سوية وغير منتظمة لعمل القلب وضرباته .</li><li>قد تسبب الأدوية الأخرى المستخدمة في علاج الربو (theophylline aminophylline or steriods) و الأدوية المدرة للبول و أقراص (Water Tablets) نفصاً في مستوى بوتاسيوم الدم.</li><li>قد تزيد بعضا من العقاقير المخدرة من خطورة نشوء حركة غير سوية وغير منتظمة لعمل&nbsp;القلب وضرباته.</li></ul><p>الحمل والإرضاع:<br />لا توجد أي بيانات سريرية عند إستخدام عقار فوستر أثناء الحمل .ينبغي عدم إستخدام فوستر . إذا<br />ما كنت حاملاً ، أو تعتقدين بأنك ربما تكونين حاملاً ، أو أنك ربما تخططين لتصبحي حاملا. ما لم<br />يخطرك طبيبك بإستخدامه أولا.<br />القيادة واستخدام الآلات والماكينات:<br />ليس لمستحضر فوستر تأثيراً على القيادة وإستخدام الآلات والماكينات.<br />يحتوي عقار فوستر مقداراً ضئيلاً من الكحول ، تحتوي كل بخة أو إستنشاقة من جهاز إستنشاقك ٧ ملجم من مادة الإيثانول (Ethanol).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>عليك قبل إستعمالك لجهاز الإستنشاق لأول مرة ، أو إذا كنت لم تقم بإستخدام جهاز الإستنشاق لمدة<br />14 يوماً ، أو مايزيد على ذلك . إطلاق بخة واحدة في الهواء للتأكد من أن جهاز الإستنشاق يعمل<br />بالصورة الصحيحه وعليك متى ما كان ذلك ممكناً . الوقوف ، أو الجلوس ، في وضع قائم مستقيم<br />عند إستنشاقك للدواء.<br />١.قم بإزالة الغطاء الواقي من قطعة الفم (البزباز) وتأكد من أن قطعة الفم نظيفة وخالية من أي<br />غبار و قاذورات&nbsp;، أومن أي أجسام أخرى غريبة.<br />٢. مارس عملية الزفير ببطء وبصورة كاملة بقدر الإمكان.<br />٣.إمسك بجسم قنينة جهاز الإستنشاق في وضع رأسي مع إتجاه جسمها إلى أعلى ، ضم شفتيك<br />حول قطعة الفم (البزباز )، لا تقم بالعض على قطعة الفم.</p><p>٤.إستنشق الهواء ببطء وبعمق من خلال فمك واضغط على الجزء العلوي من جهاز الإستنشاق<br />لإطلاق وبخ جرعة واحدة ، وذلك بعد بدئك في الإستنشاق مباشرة.<br />٥. أكتم نفسك لأطول فترة ممكنة وفي النهاية قم بنزع وإزالة جهاز الإستنشاق من فمك ومارس<br />عملية الزفير ببطء .لا تزفر عبر جهاز الإستنشاق.<br />بعد الإستعمال ، قم بإغلاق قطعة الفم (البزباز) بالغطاء الواقي.<br />وإذا ما كنت تحتاج لتناول بخة أخرى ، أمسك بجهاز الإستنشاق في وضع قائم مستقيم لمدة نص<br />. دقيقة وقم بتكرار الخطوات من ٢ إلى ٥ .</p><p>هام :لا تسرع في تطبيق الخطوات من ٢ إلى ٥<br />إذا ما شاهدت . بعد الإستنشاق ضباباً يخرج من جهاز الإستنشاق ، أو من جنبات فمك ، ينبغي<br />.( عليك البدء مرةً أخرى من الخطوة ( ٢).<br />إذا ما كانت يداك ضعيفتان ، قد يكون من الأسهل بالنسبة لك ، إمساك الإستنشاق وابهامك على<br />قاعدته.<br />وللتقليل من خطورة التعرض لإصابة فطرية في الفم والزور ، أشطف فمك ، قم بالغرغرة بالماء ،<br />أو فرش أسنانك بعد إستعمالك لجهاز إستنشاقك.<br />إذا ما كنت تعتقد أن أثر دواء فوستر كبير جداً ، أو غير كافي ، أخبر طبيبك ، أو الصيدلي بذلك.<br />&nbsp;اذا كنت تجد صعوبة في إستخدام البخاخ أثناء بداية التنفس يمكنك إستخدام جهاز (Aerochaber plus Spacer)&nbsp;<br />إسأل طبيبك أو الصيدلي او الممرضة عن هذا الجهاز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>إن دواء فوستر له مثله مثل كافة الأدوية تأثيرات جانبيه ، مع أن هذه الأعراض لا تصيب كل فرد .<br />إلا أن الكثيرين من مستخدمي جهاز الإستنشاق هذا ليس لديهم مشاكل مع الجهاز إطلاقاً.<br />كما هو الحال بالنسبة لعلاجات بأجهزة إستنشاق أخرى فإن هناك خطورة لتفاقم وسوء ضيق التنفس<br />وعسره وكذلك الأزيز بصورة فورية بعد إستعمال فوستر وتعرف هذه الحالة بإسم :التشنج الشعبي&nbsp;التناقضي .إذا ماحدث هذا ، ينبغي عليك وقف إستعمال فوستر فوراً واستعمال جهاز إستنشاقك المزيل للألم السريع المفعول فوراً ، لعلاج أعراض ضيق التنفس والأزيز.<br />إتصل بطبيبك فوراً ، إذا شعرت بأي من اعراض فرط الحساسية ، مثل حساسيات الجلد ، إحمرار الجلد ، وتورم الجلد ، أو الأغشية المخاطية ، خصوصاً العيون والوجه والشفتين وكذلك الحكة والطفح الجلدي.</p><p>تجدون أدناه قائمة بالتأثيرات الجانبية المحتملة ، وفقاً لتكرارها وتواترها.<br />تأثيرات جانبية عامة (تصيب أقل من ١ في كل ١٠ أشخاص) :<br />صداع ، صوت أجش ، التهاب الزور والحلق ، إصابات فطريه للفم والزور.<br />الإلتهاب الرئوي عند المرضى الذين يعانون من الإنسداد الرئوي المزمن<br />قم بإخبار طبيبك إذا كنت تعاني من أحد هذه الأعراض عند استخدام فوستر فقد تكون أحد أعراض<br />عدوى الرئة :</p><ul><li>حمى أو قشعريرة.&nbsp;</li><li>زيادة إفرازالمخاط وتغير لونه .</li><li>زيادة الكحة أو زيادة الصعوبة في التنفس .</li></ul><p>تأثيرات غيرعامة (تؤثر على ما يقل عن ١ في كل ١٠٠ شخص) :<br />خفقان ضربات القلب وإضطرابات في حركة وعمل القلب غير منتظمة ، عادةً ما تكون بصورة غير عادية و غير مألوفة ، وكذلك تغييرات في تخطيط القلب&nbsp;(ECO).<br />أعراض أنفلونزا ، إصابات مهبل فطرية ، إلتهاب الجيوب الأنفية (جيوب أنفية) إلتهاب الغشاء الداخلي للأنف ،(إلتهاب الأنف) ، إلتهاب الأذن ، تهيج الحلق، السعال ، سعال منتج ، نوبات ربو ، الإحساس بالمرض والإعياء ، حاسة ذوق غير سوية أو متغيره ، حرقان الشفاه ، جفاف الفم ، صعوبات في البلع ، سوء هضم ، إضطرابات معدية ، إسهال.<br />آلام عضلات ، حالات مغص ، إحمرار الوجه ، زيادة تدفق الدم في قطاعات معينة من الجسم ، الإفراط في التعرق ،الإرتجاف ، القلق ، الدوار،طفح القراص أو قشعريرة.<br />تغير بعض من مكونات الدم ، نقص في عدد كريات الدم البيضاء ، زيادة في عدد صفائح الدم ،<br />نقص في مستويات بوتاسيوم الدم ، زيادة في مستوى سكر الدم ، زيادة في مستويات أنسولين الدم ، أحماض دهنية طليقة وكيتونز&nbsp;(Ketones)<br />تأثيرات غيرعامة ( لدى مرضى الإنسداد الرئوي المزمن):</p><ul><li>إنخفاض في مستوى الكورتيزول في الدم وذلك بسبب تأثير مادة كورتيكوسيترويد في الغدة الكظرية.</li><li>عدم إنتظام ضربات القلب .</li></ul><p>تأثيرات نادراً ماتظهر (تؤثر على ما يقل عن ١ في كل ٠٠٠.١ شخص) :<br />الإحساس بالضيق في الصدر ، ضربة قلب مفقودة (تسببها تقلصات بطينية مبكرة قبل الأوان )،<br />زيادة أو نقصان في ضغط الدم ، إلتهاب الكلى ، تورم الجلد والغشاء المخاطي يستمر لعدة أيام .</p><p>تأثيرات جانبية نادرة جداً (تؤثر على ما يقل عن 1 في كل ٠٠٠.١٠ شخص) :<br />ضيق في التنفس سوء وتفاقم الربو، نقص في عدد صفائح الدم ، تورم اليدين والقدمين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- أحفظ هذا الدواء بعيداً عن نظر ومتناول الأطفال.<br />- بعد رج وخلط العلبة لايخزن فوق ٣٠ درجة مئوية بحد أقص لمدة شهرين<br />- لا تستعمل فوستر لما يزيد عن ٥ أشهر بعد خلط ورج العلبة ولا تستعمله بعد تاريخ إنتهاء الصلاحية المطبوع على العبوة والبطاقة.<br />- لا تخزن جهاز الإستنشاق في درجة حرارة تزيد عن ٣٠ درجة مئوية</p><p>&nbsp;- إذا ماكان جهاز الإستنشاق قد تعرض للبرد ، قم بإخراج الـ &quot;Canister&quot; من داخل قطعة&nbsp;الفم (البزباز) وقم بتدفئتها بكلتا يديك لدقائق قليلة ، قبل إستعمالها .لا تقم بتدفئتها بوسائل إصطناعية.<br />- تحذير: يحتوي وعاء الدواء&nbsp;&quot;Canister&quot;.&nbsp;سائلاً مضغوطاً .لا تعرضها لدرجة حرارة أعلى من ٥٠ درجة مئوية .لاتثقب علبة الدواء &quot;Canister&quot;<br />ينبغي عدم التخلص من الأدوية عن طريق الفضلات المائية ، أو النفايات المنزلية .إسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية ، التي لم تعد تحتاج إليها .</p><p>إن هذا سوف يساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المكونات النشطة الفعالة هي :بيكلوميتا زون دايبروبيونيت ، فورموتيرول فيوماريت دايهايدريت.<br />تحتوي كل نفخة من جرعة محددة من صمام قياس تحديد الجرعة على ١٠٠ مايكرو جرام من مادة بيكلوميتاسون دايبروبيونيت<br />و ٦ مايكرو جرام من مادة فورموتيرول دايهايدريت وهذا يماثل جرعة مستنشقة مرسلة من قطعة<br />الفم( البزباز) لما يساوي ٤,٨٦ مايكروجرام من مادة بيكلوميتاسون دايبروبيونيت ٠,٥ مايكرو جرام<br />من مادة فورموتيرول فيوماريت.<br />أما المكونات الأخرى فهي إيثانول لامائي حامض الهيدروليك ، دافع: نورفلورانس (HFA 134a).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>na</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>المركز الوطني للتيقظ الدوائي (NPC):<br />&bull;&nbsp;&nbsp; &nbsp;الفاكس: 966112057662 +<br />&bull;&nbsp;&nbsp; &nbsp;للاتصال بالمركز الوطني للتيقظ الدوائي: 966112038222+، تحويلة: 2317-2356-2340<br />&bull;&nbsp;&nbsp; &nbsp;مركز الاتصال &nbsp;بالهيئة العامة للغذاء والدواء: 19999<br />&bull;&nbsp;&nbsp; &nbsp;البريد الإلكتروني: npc.drug@sfda.gov.sa<br />&bull;&nbsp;&nbsp; &nbsp;الموقع الإلكتروني: https://ade.sfda.gov.sa/</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            na
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Foster100/6 microgramsper actuation pressurised inhalation solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each metered dose (ex-valve) dose contains:100 micrograms of beclometasone dipropionate and 6  micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator)   of84.6micrograms of beclometasone dipropionate and 5.0 micrograms of formoterol fumaratedihydrate.For a full list of excipients see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pressurised inhalation solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fosteris indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: -patients not adequately controlled with inhaled corticosteroids and &#39;as needed&#39; inhaled short-acting beta2-agonist or-patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. Note: Foster is not appropriate for treatment of acute asthma attacks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fosteris for inhalation use.</p><p>Fosteris not intended for the initial management of asthma. The dosage of the components of Foster is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination products is initiated but also when the dose is adjusted. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of beta-2-agonists and/or corticosteroids by individual inhalers should be prescribed.Beclometasone dipropionate in Fosteris characterised by an extrafine particle size distribution which results in a more potent effect than formulations of beclometasone dipropionate with a non-extrafine particle size distribution (100 micrograms of beclometasone dipropionate extrafine in Foster are equivalent to 250 micrograms of beclometasone dipropionate in a non-extrafineformulation). Therefore the total daily dose of beclometasone dipropionate administered inFoster should be lower than the total daily dose of beclometasone dipropionate administered in anon-extrafine beclometasone dipropionate formulation.This should be taken into consideration when a patient is transferred from beclometasone dipropionate non-extrafine formulations to Foster; the dose of beclometasone dipropionate should be lower and will need to be adjusted to the individual needsof patients.</p><p>Dose recommendations for adults 18 years and above: One or two inhalations twice daily. The maximum daily dose is 4 inhalations daily.Dose recommendations for children and adolescents under 18 years:There is no experience with Fosterin children andadolescents under 18 years of age. Therefore Foster is not recommended for children and adolescents under 18 years until further data become available.</p><p>Patients should be regularly reassessed by a doctor, so that the dosage of Fosterremains optimaland is only changed on medical advice.The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. When control of symptoms is maintained with the lowest recommended dosage, then the next step could include a test of inhaled corticosteroid alone. Patients should be advised to take Fosterevery day even when asymptomatic.Special patient groups: There is no need to adjust the dose in elderly patients. There are no data available for use of Fosterin patients with hepatic or renal impairment (see section 5.2). Instructions for useTo ensure proper administration of the drug, the patient should be shown how to use the inhaler correctly by a physician or other health professional. Correct use of the pressurised metereddose inhaler is essential in order that treatment is successful. The patient should be advised to read the Patient Information Leaflet carefully and follow the instructions for use as given in the Leaflet.</p><p>Before using the inhaler for the first time or if the inhaler has not been used for 14 days or more, one actuation should be released into the air in order to ensure that the inhaler is working properly. Wheneverpossible patients shouldstand or sit in an upright position when inhalingfrom their inhaler.The steps below should be followed:1. Remove the protectivecap from the mouthpieceand check that the mouthpiece is clean and free from dust and dirt or any other foreign objects.2. Breathe out as slowly and deeply as possible.3. Hold the canister vertically with its body upwards and put the lips around the mouthpiece.Do not bite the mouthpiece4. At the same time, breathe in slowly and deeply through the mouth. After starting to breathein, press down on the top of the inhaler to release one puff.5. Hold the breath for as long as possible and, finally, remove the inhaler from the mouth and breathe out slowly. Do not breath out into the inhaler.Should a further puff beneeded, keep the inhaler in a vertical position for about half a minuteandrepeat steps 2 to 5.After use, close with protectivecap.IMPORTANT: do not perform steps 2 to 5 too quickly.If mist appears following inhalation, either from the inhaler or from the sides of the mouth, the procedure should be repeatedfrom step 2.For patients with weak hands it maybe easier to hold the inhaler with both hands. Thereforethe index fingers should be placed on the top of the inhaler canister and both thumbs on the base of the inhaler.</p><p>Patients should rinse their mouth or gargle with water or brush the teethafter inhaling (see section 4.4).Cleaning Patients should be advised to read the Patient Information Leaflet carefully for cleaning instructions.For the regular cleaning of the inhaler, patients should remove the cap from themouthpiece and wipe the outside and inside of the mouthpiece with a dry cloth. They should not use water or other liquids to clean the mouthpiece.There are no clinical data available on the use of Fosterwith a spacer, therefore the recommended posologyrefers to the inhalation of the medicinal product without a spacer (with a standard actuator).</p><p>Fostermust not be used with any spacing device; if a spacing device is required the patients should have their treatment changed to either an alternative pressurised metered dose inhaler with a named spacing device or an inhalation powder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to beclometasone dipropionate, formoterol fumarate dihydrate and/or any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fostershould be used with caution (which may include monitoring)in patients with cardiac arrhythmias, especiallythird degree atrioventricular blockand tachyarrhythmias(accelerated and/or irregular heart beat), idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, severe heart disease, particularlyacute myocardial infarction, ischaemicheart disease, congestive heart failure, occlusive vascular diseases, particularlyarteriosclerosis, arterial hypertension and aneurysm.Caution should also be observed when treating patients with known or suspected prolongation of the QTc interval, eithercongenital or drug induced (QTc &gt; 0.44 seconds). Formoterol itself may induce prolongation of the QTc interval.Caution is also required when Foster is used by patients with thyrotoxicosis, diabetes mellitus, phaeochromocytoma and untreated hypokalaemia.Potentially serious hypokalaemia may result from beta2-agonist therapy. Particular caution is advised in severe asthma as this effect may be potentiated by hypoxia. Hypokalaemia may also be potentiated by concomitant treatment with other drugs which can induce hypokalaemia, such as xanthine derivatives, steroids and diuretics (see Section 4.5). Caution is also recommended in unstable asthma when a number of &ldquo;rescue&rdquo; bronchodilators may be used.It is recommended that serum potassium levels are monitored in such situations.</p><p>The inhalation of formoterol may cause a rise in blood glucoselevels. Thereforeblood glucose should be closely monitored in patients with diabetes. If anaesthesia with halogenated anaesthetics is planned, it should be ensured that Fosteris not administered for at least 12 hours before the start of anaesthesiaas there is a risk of cardiac arrhythmias. As with all inhaled medication containing corticosteroids, FOSTER should be administered with caution in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.It is recommended that treatment with FOSTER should not be stoppedabruptly.</p><p>If patients find the treatment ineffective medical attention must be sought. Increasing use of rescue bronchodilators indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy. Sudden and progressive deterioration in control of asthma is potentially life threatening and the patient should undergo urgent medical assessment.Consideration should be given to the need for increase treatmentwith corticosteroids, either inhaled or oral therapy, or antibiotic treatment if an infection is suspected.Patients should not be initiated on Foster during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma. Serious asthma-related adverse events and exacerbations may occur during treatment with Foster. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on Foster.As with other inhalation therapy paradoxical bronchospasm may occur withan immediate increase in wheezing and shortness of breathafter dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. Fostershould be discontinued immediately, the patient assessed and alternative therapy instituted if necessary. Foster should not be used as the first treatment for asthma.For treatment of acute asthma attacks patients should be advised to have their short-acting bronchodilator available at all times.</p><p>Patients should be reminded to take Fosterdaily as prescribed even when asymptomatic. Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of Foster. Regular review of patients as treatment is stepped down is important. The lowest effective dose of Fostershould be used (see section 4.2).Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhaled than with oral corticosteroids. Possible systemic effects include: Cushing&#39;s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Therefore, it is important that the patient is reviewed regularly, and the dose of inhaled corticosteroid is reduced to the lowest dose at which effective control of asthma is maintained.Prolonged treatment of patients with high doses of inhaled corticosteroids may result in adrenal suppression and acute adrenal crisis. Childrenaged less than 16 years taking/inhaling higher than recommended doses of beclometasone dipropionate may be at particular risk. Situations which could potentially trigger acute adrenal crisis, include trauma, surgery, infection or any rapid reduction in dosage. Presenting symptoms are typically vague and may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, hypotension, decreased level of consciousness, hypoglycaemia, and seizures. Additional systemic corticosteroid covershould be considered during periods of stress or elective surgery. Care should be taken when transferring patients to Fostertherapy, particularly if there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy.</p><p>Patients transferring from oral to inhaled corticosteroids may remain at risk of impaired adrenal reserve for a considerable time. Patients who have required high dose emergency corticosteroid therapy in the past or have received prolonged treatment with or high doses of inhaled corticosteroids may also be at risk. This possibility of residual impairment should always be borne in mind in emergency and elective situations likely to produce stress, and appropriate corticosteroid treatment must be considered. The extent of the adrenal impairment may require specialist advice before elective procedures. Patients should be advised that Foster contains a small amount of ethanol (approximately 7 mg per actuation); however at normal doses the amount of ethanol is negligible and doesnot pose a risk to patients. Patients should be advised to rinse the mouth or gargle with water or brush the teethafter inhaling the prescribed dose to minimise the risk of oropharyngeal candida infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic interactionsBeclometasone dipropionate undergoes a very rapid metabolism via esterase enzymes without involvement of cytochrome P450 system.</p><p>Pharmacodynamic interactionsBeta-blockers (including eye drops) should be avoided in asthmatic patients. If beta-blockers are administered for compelling reasons, the effect of formoterol will be reduced or abolished.On the other hand, concomitant use of other beta-adrenergic drugs can have potentially additiveeffects, therefore caution is required whentheophylline or other beta-adrenerigic drugs are prescribed concomitantly with formoterol. Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines, monoamine oxidase inhibitors and tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular arrhythmias. In addition L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards beta2-sympathomimetics. Concomitant treatment with monoamine oxidase inhibitors including agents with similar properties such as furazolidone and procarbazine may precipitate hypertensive reactions. There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons. Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalaemic effect of beta2-agonists (see section 4.4.).Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides. Foster contains a small amount of ethanol. There is a theoretical potential for interaction in particularly sensitive patients taking disulfiram or metronidazole</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with or evidence of safety of propellant HFA-134a in human pregnancy or lactation. However studies of the effect of HFA-134a on reproductive function and embryofetal development in animals have revealed no clinically relevant adverse effects.Pregnancy There are no relevant clinical data on the use of Fosterin pregnant women. Animal studies using beclometasone dipropionate and formoterol combination showed evidence of toxicity to reproduction after high systemic exposure (see 5.3 Preclinical safety data). Because of the tocolytic actions of beta2-sympathomimetic agents particular care should be exercised in the run up to delivery.Formoterol should not be recommended for use during pregnancy and particularly at the end of pregnancy or during labour unless there is no other (safer) established alternative. Foster should only be used during pregnancy if the expected benefits outweigh the potential risks.LactationThere are no relevant clinical data on the use of Foster in lactation in humans.Although no data from animal experiments are available, it is reasonable to assume that beclometasone dipropionate is secreted in milk, like other corticosteroids. While it is not known whether formoterol passes into human breast milk, it has been detected in the milk of lactating animals. Administration of Foster to women who are breast-feeding should only be considered if the expected benefits outweigh the potential risks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fosteris unlikely to have any effect on the ability to drive and operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As Fostercontains beclometasone dipropionate and formoterol fumarate dihydrate, the type and severity of adverse reactions associated with each of the compounds may beexpected. There is no incidence of additional adverse events following concurrent administration of the two compounds. Undesirable effects which have been associated with beclometasone dipropionate and formoterol administered as a fixed combination (Foster) and as single agents are given below, listed by system organ class. Frequencies are defined as: very common (1/10),common (1/100 and &lt;1/10),uncommon (1/1,000 and &lt;1/100), rare (1/10,000 &lt; 1/1,000) and very rare (&le;1/10,000).Common and uncommonADRs were derived from clinical trial data. The incidence on placebo was not taken into account.</p><p>System Organ ClassAdverse ReactionFrequencyInfections and PharyngitisCommon</p><p>nfestationsInfluenza, oral fungal infection, pharyngeal and oesophagealcandidiasis, vaginal candidiasis, gastroenteritis, sinusitisUncommonBlood and the lymphatic system disordersGranulocytopeniaUncommonThrombocytopeniaVery rare Immune system disordersDermatitis allergicUncommonHypersensitivity reactions, including erythema, lips, face, eyeand pharyngeal oedemaVeryrare Endocrine disordersAdrenal suppressionVery rare Metabolism and nutrition disordersHypokalaemia, hyperglycaemiaUncommon</p><p>Psychiatric disordersRestlessnessUncommonAbnormal behaviour, sleep disorder, hallucination Very rare Nervous system disordersHeadacheCommonTremor, dizziness, UncommonEye disordersGlaucoma, cataractVery rare Ear and labyrinth disordersOtosalpingitisUncommonCardiac disordersPalpitations, electrocardiogram QT corrected interval prolonged, electrocardiogram change, tachycardia, tachyarrhythmiaUncommonVentricular extrasystoles, angina pectorisRare</p><p>Atrial fibrillationVery rare Vascular disordersHyperaemia, flushing UncommonRespiratory,thoracic and mediastinal disordersDysphoniaCommonRhinitis, cough, productive cough, throat irritation, asthmatic crisisUncommonBronchospasm paradoxicalRareDyspnoea, exacerbation of asthmaVery rare Gastrointestinal disordersDiarrhoea, dry mouth, dyspepsia, dysphagia, burning sensation of the lips, nausea, dysgeusiaUncommonSkin and subcutaneous tissue disordersPruritus, rash, hyperhidrosisUncommonUrticaria, angioneurotic oedemaRareMusculoskeletal, connective tissue and bone disordersMuscle spasms, myalgiaUncommonGrowth retardation in children and adolescentsVery rareRenal and urinary disordersNephritisRareGeneral disorders and administration site conditionsOedema peripheralVery rare InvestigationsC-reactive proteinincreased, platelet count increased, free fatty acids increased, blood insulin increased, blood ketone body increasedUncommonBlood pressure increased, blood pressure decreasedRare</p><p>Bone density decreasedVery rare</p><p>As with other inhalation therapy, paradoxical bronchospasm may occur (see 4.4 &#39;Special Warnings and Precautions for Use&#39;).Among the observed adverse reactions those typically associated with formoterol are: hypokalaemia, headache, tremor, palpitations, cough,muscle spasmsand prolongation of QTc interval. Adverse reactions typically associated with the administration of beclometasone dipropionate are: oral fungal infections, oral candidiasis, dysphonia, throat irritation. Dysphonia and candidiasis may be relieved by gargling or rinsing the mouth with water or brushing the teethafter using the product. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst continuing the treatment with Foster.Systemic effects ofinhaled corticosteroids (e.g. beclometasonedipropionate) may occur particularly when administered at high doses prescribed for prolonged periods, these may include adrenal suppression, decrease in bone mineral density, growth retardation in children and adolescents, cataract and glaucoma (see also4.4).Hypersensitivity reactions including rash, urticaria pruritus, erhythema and oedema of the eyes, face, lips and throat may also occur.To report any side effect(s):The National Pharmacovigilance and Drug Safety Center (NPC)Fax +966-11-205-7662Call NPC at +966-11-2038222, Exts 2317-2356-2353-2354-2334-2340Tool Free Phone: 8002490000E-mail: npc.drug@sfda.gov.saWebsite: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inhaled doses of Fosterup to twelve cumulative actuations (total beclometasone dipropionate1200 micrograms, Formoterol 72 micrograms) have been studied in asthmatic patients. The cumulative treatments did not cause abnormal effect on vital signs and neither serious nor severe adverse events were observed. Excessive doses of formoterol may leadto effects that are typical of beta2-adrenergic agonists: nausea, vomiting, headache, tremor, somnolence, palpitations, tachycardia, ventricular arrhythmias, prolongation of QTc interval, metabolic acidosis, hypokalaemia, hyperglycaemia.&nbsp;In case of overdose of formoterol, supportive and symptomatic treatment is indicated. Serious cases should be hospitalised. Use of cardioselective beta-adrenergic blockers may be considered, but only subject to extreme caution since the use of beta-adrenergic blocker medication may provoke bronchospasm.Serum potassium should be monitored.Acute inhalation of beclometasone dipropionate doses in excess of those recommended may lead to temporary suppression of adrenal function. This does not need emergency action as adrenal function is recovers in a few days, as verified by plasma cortisol measurements. In these patients treatment should be continued at a dose sufficient to control asthma.Chronic overdose of inhaled beclometasone dipropionate: risk of adrenal suppression(seesection 4.4.). Monitoring of adrenal reserve may be necessary. Treatment should be continued at a dose sufficient to control asthma</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Adrenergics and other drugs for obstructive airway diseases. ATC-code: R03 AK07.Mechanisms of action and pharmacodynamic effectsFostercontains beclometasone dipropionate and formoterol, which have different modes of action. In common with other inhaled corticosteroids and beta2-agonists combinations, additive effects are seen in terms of reduction of asthma exacerbations.Beclometasone dipropionateBeclometasone dipropionate given by inhalation at recommended doses has a glucocorticoid antiinflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma with less adverse effects than when corticosteroids are administered systemically. Formoterol Formoterol is a selective beta2-adrenergic agonist that produces relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect sets in rapidly, within 1-3 minutes after inhalation, and has a duration of 12 hours after a single dose. FOSTER In clinical trials in adults, the addition of formoterol to beclometasone dipropionate improved asthma symptoms and lung function and reduced exacerbations. In a 24-week study the effect on lung function of Fosterwas at least equal to that of the free combination of beclomeasone dipropionate and formoterol, and exceeded that of beclometasone dipropionate alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The systemic exposure to the active substances beclometasone dipropionate and formoterol in the fixed combination Fosterhave been compared to the single components.In a pharmacokinetic study conducted in healthy subjects treated with a single dose of Foster fixed combination (4 puffs of 100/6 micrograms) or a single dose of beclometasone dipropionate CFC (4 puffs of 250 micrograms) and Formoterol HFA (4 puffs of 6 micrograms), the AUC of beclometasone dipropionatemain active metabolite (beclometasone-17-monopropionate), and its maximal plasma concentration were, respectively, 35% and 19% lower withthe fixed combination, than with non-extrafine beclometasone dipropionate CFC formulation, in contrast,the rate of absorption was more rapid (0.5 vs 2h)with the fixed combination compared to non-extrafine beclometasone dipropionate CFC alone. For formoterol, maximal plasma concentration was similar after administration of the fixed or the extemporary combination and the systemic exposure was slightly higher after administration of Fosterthan with the extemporary combination.&nbsp;There was no evidence of pharmacokinetic or pharmacodynamic (systemic) interactions between beclometasone dipropionateand formoterol. Beclometasone dipropionate Beclometasone dipropionateis a pro-drug with weak glucocorticoid receptor binding affinity that is hydrolysed via esterase enzymes to an active metabolite beclometasone-17-monopropionate which has a morepotent topical anti-inflammatory activity compared with the pro-drug beclometasone dipropionate.Absorption distributionand metabolismInhaled beclometasone dipropionateis rapidly absorbed through the lungs; prior to absorption there is extensive conversion to its active metabolitebeclometasone-17-monopropionate via esterase enzymes that are found in most tissues. The systemic availability of beclometasone-17-monopropionatearises from lung (36%) and from gastrointestinal absorption of the swallowed dose. The bioavailability of swallowed beclometasone dipropionateis negligible however, pre-systemic conversion to beclometasone-17-monopropionateresults in 41%of the dose being absorbedas the active metabolite.There is an approximately linear increase in systemic exposure with increasing inhaled dose. The absolute bioavailability following inhalation is approximately 2% and 62% of the nominal dose for unchanged beclometasone dipropionate and beclometasone-17-monopropionaterespectively.Following intravenous dosing, the disposition of beclometasone dipropionateand its active metaboliteare characterised by high plasma clearance (150 and 120L/h respectively), with a small volume of distribution at steady state for beclometasone dipropionate(20L) and larger tissue distribution for its active metabolite (424L).Plasma protein binding is moderately high.</p><p>ExcretionFaecal excretion is the major route of beclometasone dipropionate elimination mainly as polar metabolites. The renal excretion of beclometasone dipropionateand its metabolites is negligible. The terminal elimination half-lives are 0.5 h and 2.7 h for beclometasone dipropionateand beclometasone-17-monopropionate respectively.&nbsp;Special populationsAs beclometasone dipropionateundergoes a veryrapid metabolism via esterase enzymes present in intestinal fluid, serum, lungs and liver, to originate the more polar productsbeclometasone-21-monopropionate, beclometasone-17-monopropionate,and beclometasonehepatic impairment is not expected to modify the pharmacokinetics and safety profile ofbeclometasone dipropionate.The pharmacokinetics of beclometasone dipropionatein patients with renal impairment has not been studied. As beclometasone dipropionateor its metabolites were not traced in the urine, an increase in systemic exposure is not envisaged in patients with renal impairment. FormoterolAbsorption and distributionFollowing inhalation, formoterol is absorbed both from the lung and from the gastrointestinal tract. The fraction of an inhaled dose that is swallowed after administration with an metered dose inhaler (MDI)may ranges between 60% and90%,At least 65% of the fraction that is swallowed is absorbed from the gastrointestinal tract.Peak plasma concentrations of unchanged drug occur within 0.5 to 1 hours after oral administration. Plasma protein binding of formoterol is 61-64% with 34% bound to albumin. There was no saturation of binding in the concentration range attained with therapeutic doses.The elimination half-life determined after oral administration is 2-3 hours. Absorption of formoterol is linear following inhalation of 12 to 96 &mu;g of formoterol fumarate.MetabolismFormoterol is widely metabolised and the prominent pathway involves direct conjugation at the phenolic hydroxyl group. Glucuronide acid conjugate is inactive. The second major pathway involves O-demethylation followed by conjugation at the phenolic 2&rsquo;-hydroxyl group. Cytochrome P450 isoenzymes CYP2D6, CYP2C19 and CYP2C9 are involved in the O-demethylation of formoterol. Liver appears to be the primary site of metabolism. Formoterol does not inhibit CYP450 enzymes at therapeutically relevant concentrations.ExcretionThe cumulative urinary excretion of formoterol after single inhalation from a dry powder inhalerincreased linearly in the 12 &ndash; 96 &mu;g dose range. On average, 8% and 25% of the dose was excreted as unchanged and total formoterol, respectively. Based on plasma concentrations measured following inhalation of a single 120 &mu;g dose by 12 healthy subjects, the mean terminal elimination half-life was determined to be 10 hours. The (R,R)- and (S,S)-enantiomers represented about 40% and 60% of unchanged drug excreted in the urine, respectively. The relative proportion of the two enantiomers remained constant over the dose range studied and there was no evidence of relative accumulation of one enantiomer over the other after repeated dosing.</p><p>After oral administration (40 to 80 &mu;g), 6% to 10% of the dose was recovered in urine as unchanged drug in healthy subjects; up to 8% of the dose was recovered as the glucuronide.A total 67% of an oral dose of formoterol is excreted in urine (mainly as metabolites) and the remainder in the faeces. The renal clearance of formoterol is 150 ml/min.</p><p>Special populationsHepatic/Renal impairment: the pharmacokinetics of formoterol has not been studied in patients with hepatic or renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicity observed in animal studies with beclometasone dipropionate and formoterol, given in combination or separately, consisted mainly of effects associated with exaggerated pharmacological activity. They are related to the immuno-suppressive activityof beclometasone dipropionateand to the known cardiovascular effects of formoterol evident mainly in dogs. Neither increase in toxicity nor occurrence of unexpected findings were observedupon administration of the combination. Reproduction studies in rats showed dose-dependent effects. The combination was associated with reduced female fertility and embryofetal toxicity. High doses of corticosteroids to pregnant animals are known to cause abnormalities of fetal development including cleft palate and intra-uterine growth retardation, and it is likely that the effects seen with the beclometasone dipropionate/formoterol combination were due to beclometasone dipropionate. Theseeffects were noted only with high systemic exposure tothe active metabolite beclometasone-17-monoproprionate(200 fold the expected plasma levels in patients). Additionally, increased duration of gestation and parturition, an effect attributable to the known tocolytic effects of beta2-sympathomimetics, was seen in animal studies. These effects were noted when maternal plasma formoterol levels were below the levels expected in patients treated with Foster.Genotoxicity studies performed with a beclometasone dipropionate /formoterol combination do not indicate mutagenic potential. No carcinogenicity studies have been performed with the proposed combination. However animal data reported for the individual constituents do not suggest any potential risk of carcinogenicity in man.Preclinical data on the CFC free propellant HFA-134a reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Norflurane(HFA-134a)EthanolanhydrousHydrochloric acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prior to dispensing to the patient:Store in a refrigerator (2-8&deg;C) (for a maximum of 15 months).After dispensing:Do not store above 30&deg;C (for a maximum of 2 months).The canister contains a pressurised liquid. Do not expose to temperatures higher than 50&deg;C. Do not pierce the canister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The inhalation solution is contained in a pressurised aluminium container sealed with a metering valve and fitted into a polypropyleneplastic actuatorwhich incorporates a mouthpiece and is provided witha plastic protective cap. Each pack contains:1 pressurised container which provides 120 actuations</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For pharmacies:Enter the date of dispensing to the patient on the pack. Ensure that there is a period of at least 2 months between the date of dispensing and the expiry date printed on the pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chiesi Farmaceutici S.p.A.Via Palermo 26/A43122ParmaItaly
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/10/2010
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>